ExoCoBio

What ExoCoBio does

ExoCoBio is a South Korea-based biotechnology company founded in 2017 that develops therapeutics and cosmetic products based on stem cell-derived exosomes. Its core proprietary platform is ExoSCRT, a patented isolation and purification technology (Patent No. 10-1895916) that produces 0.1-0.5% high-purity exosomes from stem cell conditioned media at industrial scale. The technology underpins both the consumer/professional aesthetics portfolio (ASCE+ Skin, ASCE+ Hair, ASCE+ Intimate, EXOCODE, Exomage, Celltweet, Lapuroon, Celosome) and a B2B ingredient business supplying ExoBRID-E, Vexosome, and Rose Exosome to cosmetic manufacturers globally.

The company operates a vertically integrated model spanning R&D, GMP manufacturing (via the ExoGMP facility in Osong completed in 2022, described as the world's first exosome biopharmaceutical GMP plant), regulatory licensure (Korea MFDS GMP, Brazil ANVISA Class IV, ISO 13485/9001/22716), and multi-channel distribution. Go-to-market combines B2B ingredient sales through exclusive distributors (Hokkaido Natural Bio in Japan, PRSS Japan, LG Chem domestically), direct professional sales to dermatology and aesthetic medicine clinics for the ASCE+ line, and US market access via the 2023 acquisition of BENEV, a US medical aesthetic company with 80 physicians. End customers include licensed dermatologists, aesthetic medicine practitioners, cosmetic manufacturers, and—through BENEV—US medical spas.

The business model is multi-stream: B2B ingredient sales to cosmetic companies, professional product sales through clinics and medical aesthetic practices, GMP contract manufacturing services for pharmaceutical-grade exosomes, and combined US revenue via BENEV. Reported cumulative sales since the 2023 BENEV combination reach 680 billion KRW. The company is pursuing biopharmaceutical pipeline expansion (ACET immuno-oncology, atopic dermatitis, IBD, acute kidney injury, alopecia) alongside a planned KOSDAQ listing signaled by 2020 Pre-IPO financing and continued corporate governance activity through 2025.

Name

ExoCoBio

Legal name

주식회사 엑소코바이오

Website

https://exocobio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

ExoCoBio is a South Korean biotechnology company that develops stem cell-derived exosome therapeutics and cosmetic ingredients via its proprietary ExoSCRT platform. It serves dermatology clinics, aesthetic medicine practitioners, cosmetic manufacturers, and (via BENEV) US medical aesthetics practices.

Ownership category

akta.pro rank

Product category

Regenerative Aesthetics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Exosome & Extracellular Vesicle (EV) Therapeutics (HLAMANAE), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Exosome biotechnology
• Regenerative aesthetics
• Cosmetic raw materials
• Stem cell exosomes
• Biopharmaceutical development

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. ASCE+ Professional Aesthetic Products: Sale of professional-grade exosome skincare products (ASCE+ Skin, ASCE+ Hair, ASCE+ Intimate) through dermatology clinics and medical aesthetic practices. Revenue target of 200 billion KRW with profitability focus post-2023 BENEV acquisition.
2. Exosome Ingredient Sales (B2B Raw Materials): Supply of proprietary exosome ingredients including ExoBRID-E (human-derived), ExoBRID-R (rose-derived), Vexosome, and Rose Exosome to cosmetic manufacturers globally through exclusive distribution agreements.
3. ExoSCRT Contract Manufacturing: GMP exosome manufacturing services leveraging ExoGMP facility for clinical-grade exosome production for pharmaceutical applications.
4. BENEV Acquisition Integration: Combined operations with acquired US medical aesthetic company BENEV, achieving 680 billion KRW in cumulative sales since 2023 business combination.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

ExoCoBio develops and commercializes exosome-based products derived from stem cells using its proprietary ExoSCRT isolation and purification technology. The company sells B2B raw material ingredients (ExoBRID-E, Vexosome, Rose Exosome) to cosmetic manufacturers worldwide, and distributes professional regenerative aesthetic skincare products (ASCE+ line and sub-brands such as Exomage, Celltweet, Lapuroon, Celosome, EXOCODE) through dermatology clinics and medical aesthetic practices. It is also building a biopharmaceutical pipeline including ACET immuno-oncology candidates.

Product overview

ExoCoBio operates as an exosome-based biomedicine and regenerative aesthetics company with a multi-brand portfolio strategy. The company offers ExoSCRT™ as its core patented exosome isolation and purification technology, which produces high-purity (0.1-0.5%) exosomes from stem cell conditioned media. The consumer-facing product portfolio includes ASCE+ (Skin, Hair, Intimate), EXOCODE, Exomage, Celltweet, Lapuroon, and Celosome brands for skincare and aesthetic applications. On the raw material side, the company provides ExoBRID-E (human-derived), Vexosome (hybrid), and Rose Exosome as bio-ingredients for cosmetic manufacturers. In biopharmaceuticals, ExoCoBio is developing ACET (immuno-oncology), Regenerative Therapeutics (Atopic Dermatitis, IBD, Acute Kidney Injury, Alopecia), and Immuno-Oncology programs based on ExoSCRT exosome technology.

Differentiator

Problem solved

Functional benefit

Brands

• ASCE+ Skin: Professional exosome-based skincare product line for skin rejuvenation and regenerative aesthetics
• ASCE+ Hair
• ASCE+ Intimate
• EXOCODE
• Exomage
• Celltweet
• ExoSCRT
• ExoBRID
• Vexosome
• Rose Exosome
• ExoGMP
• ACET

Quantifiable outcome

• Achieved 680 billion KRW in cumulative sales since 2023 business combination with BENEV
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• BENEV Company (USA)coreStrategic or Co-development Partner · 12 July 2023ExoCoBio completed acquisition of BENEV, a US-based medical aesthetic company, to enhance its exosome technology business. The deal leverages BENEV's established products and market presence in North America to accelerate growth in regenerative aesthetics. Combined operations achieved 680 billion KRW in sales since the 2023 business combination. BENEV provides access to 80 US physicians and established regulatory pathways.
• LG ChemcoreGTM or Marketing Partner · 25 November 2020MOU for joint domestic sales of ASCE+ professional anti-aging solutions. LG Chem brings extensive aesthetic product distribution network through premium filler brands YVOIRE and Y-Solution. Partnership enables ExoCoBio to leverage LG Chem's established clinic and hospital relationships in Korea for rapid market penetration of ASCE+ products.
• Hokkaido Natural Bio (HNB, Japan)majorChannel Partner/ Reseller/ Distributor · 10 January 2020Exclusive supply agreement for ExoBRID-E exosome ingredient to Japanese market. HNB is the Hokkaido Natural Bio Group, providing access to Japan's cosmetics and cosmeceutical market with ExoCoBio's proprietary high-purity exosome ingredient.
• BlueMtechmajorStrategic or Co-development PartnerStrategic partnership for exosome product distribution and market supply. BlueMtech collaboration strengthens product market reach in the aesthetic segment.
• PRSS JapanminorChannel Partner/ Reseller/ DistributorDistribution partnership for Japanese aesthetic market entry and sales expansion in Japan.
• Dr. Jan Lotvall (Former CSO)majorOthersGlobally recognized exosome expert recruited as Chief Scientific Officer to strengthen R&D and build global network. Dr. Lotvall brought extensive expertise in exosome paracrine effects and stem cell research.
• Dr. Lee Yong-won (Executive VP)minorOthersExecutive Vice President leading ExoCoBio research institute, responsible for exosome industry research review and development strategy.

Scale indicators5 records

Recent moves8 records

Expansion highlights8 records

Regional players

• Medytox: South Korean aesthetics company specializing in botulinum toxin and dermal fillers. Comparable as a Korean-based aesthetic medicine company with similar distribution through dermatology clinics; former employer of ExoCoBio's CEO Byong Seung Cho.
• Hugel: South Korean medical aesthetics company producing botulinum toxin (Botulax) and hyaluronic acid fillers. Directly comparable as a Korean competitor in professional medical aesthetics channels serving dermatologists and aesthetic clinics.

Direct peers

• BENEV Company: US medical aesthetic company acquired by ExoCoBio in 2023. Previously a peer in regenerative aesthetics distribution with established US physician network (80 doctors). Now operates as a wholly-owned subsidiary providing North American market access.
• Kimera Labs: US-based exosome company developing exosome-based regenerative therapies and aesthetic products. Directly comparable in technology platform (exosome isolation/production) and target markets (regenerative aesthetics, professional clinics).
• Rion Aesthetics: US-based company focused on platelet-derived growth factor and exosome technologies for professional aesthetic and regenerative medicine. Comparable in target customer (medical aesthetic professionals) and product format (regenerative biologics for skin rejuvenation).
• CALECIM Professional: Stem cell-derived growth factor skincare line marketed to professional aesthetic clinics. Comparable as a regenerative skincare brand using biologically active stem cell-derived components for skin rejuvenation in dermatology/aesthetics channels.

Broad incumbents

• LG Chem (Life Sciences): Diversified Korean chemical/pharma conglomerate with aesthetics franchise (YVOIRE fillers, Y-Solution). Both a GTM partner (ASCE+ distribution MOU) and a potential competitor given its established filler market presence overlapping with ExoCoBio's professional aesthetic products.
• Allergan Aesthetics (AbbVie): Global aesthetics leader (Botox, CoolSculpting, Juvéderm fillers) within AbbVie. Comparable as a broad incumbent serving dermatologists and aesthetic clinics with overlapping indications (anti-aging, skin rejuvenation) where exosome-based products increasingly compete.
• Galderma: Global dermatology and aesthetics company (Restylane, Sculptra, Dysport) serving the same dermatologist and aesthetic medicine customer base as ExoCoBio's ASCE+ products. Relevant as a broad incumbent whose fillers and biostimulators define the regenerative aesthetics market ExoCoBio targets.

Emerging players

• Direct Biologics: US exosome-based regenerative medicine company developing biologic therapies using bone marrow-derived exosomes. Comparable as an emerging exosome platform with biopharma pipeline ambitions overlapping ExoCoBio's regenerative therapeutics strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UClG4SKBlyZOMxbhNsfXIt8w
• Facebookfacebook.com/ExoCoBio
• LinkedInlinkedin.com/company/13256722
• Instagraminstagram.com/exocobio.official

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExoCoBio